Coexpression of GITRL confers resistance to Treg cell-mediated immunosuppression to anti-CD19 CAR-NK cells
By
Dayane Schmidt
Sima Ebrahimabadi
Mariane Cariati Tirapelle
Camilly Melo Ferreira
Matheus Henrique dos Santos
Alison Felipe Biggi
Mara Elisama da Silva Januário
Rodrigo Tocantins Calado
Virginia Picanço-Castro
July 7, 2026
Clinical Scorecard: Coexpression of GITR Ligand Enhances Resistance of Anti-CD19 CAR-NK Cells to Immunosuppression by Treg Cells
At a Glance
Category Detail
Condition B-cell leukemias and lymphomas Key Mechanisms Coexpression of GITR ligand enhances CAR-NK cell resistance to Treg-mediated immunosuppression. Target Population Patients with B-cell malignancies Care Setting Cancer immunotherapy
Key Highlights
CAR19-GITRL-NK cells show superior expansion and metabolic fitness. Enhanced cytotoxicity and cytokine secretion against CD19+ targets. GITRL coexpression mitigates Treg-mediated suppression. In vivo studies demonstrate improved tumor control and overall survival. RNA sequencing reveals activation of immune response pathways. Guideline-Based Recommendations
Diagnosis
Management
Utilize CAR-NK cells with GITRL coexpression for enhanced antitumor activity. Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients with B-cell leukemias and lymphomas undergoing CAR-NK cell therapy.
GITRL coexpression may improve efficacy by counteracting Treg suppression.
Clinical Best Practices
Consider GITRL coexpression in CAR-NK cell design to enhance therapeutic outcomes. Monitor for Treg activity in the tumor microenvironment during treatment. Related Resources & Content
